Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBT (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBT for 4 consecutive years, with -$5.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 152.61% to -$5.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.7 million, a 74.31% decrease, with the full-year FY2024 number at -$9.0 million, down 14.05% from a year prior.
  • EBT was -$5.0 million for Q3 2025 at bioAffinity Technologies, down from -$4.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$88052.0 in Q2 2022 to a low of -$5.0 million in Q3 2025.
  • A 4-year average of -$2.5 million and a median of -$2.1 million in 2024 define the central range for EBT.
  • Biggest YoY gain for EBT was 53.48% in 2023; the steepest drop was 1871.09% in 2023.
  • bioAffinity Technologies' EBT stood at -$1.7 million in 2022, then plummeted by 41.58% to -$2.4 million in 2023, then dropped by 25.14% to -$3.0 million in 2024, then plummeted by 70.14% to -$5.0 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's EBT are -$5.0 million (Q3 2025), -$4.0 million (Q2 2025), and -$2.7 million (Q1 2025).